Solange Arazi Caillaud. MD Emiliano Bissio. MD María Ester Lázaro. MD.

Slides:



Advertisements
Similar presentations
International Antiviral SocietyUSA Panel
Advertisements

HIV Situation in India Dr Sunil Gaikwad.
HIV/AIDS in Argentina Vanesa Fridman, MD Infectious Disease Hospital de Clinicas Universidad de Buenos Aires, Argentina.
Insight into Hungarian HIV situation 9th Advanced HIV Course, EACS , Aix en Provence Botond Lakatos, HU.
Ministry of Health National STD/AIDS Programme Universal Access to Antiretroviral Therapy: The Brazilian Experience.
ARV failure and resistance for the paediatrician
Innovative Strategies for the Management of HIV Infection Dual therapies without NRTIs Jean-Guy Baril, MD Clinique médicale du Quartier Latin CHUM This.
Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.
Pre Test !!!!!!. How many classes of HIV meds are currently available?
Antiretroviral drugs in UMMC Presenter: TE CHIN YEW Preceptor: KHOO SU LIN.
The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool
MONITORING SYSTEM FOR THE ANTIRETROVIRAL THERAPY IN BRAZIL: LESSONS LEARNED AND FUTURE DIRECTIONS Marco Vitória, MD Brazilian STD/AIDS Programme - MOH.
Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.
Rodrigo Zilli Haanwinckel Ministry of Health of Brazil Health Surveillance Secretariat Department of STD, AIDS and Hepatitis Prevention of vertical transmission.
ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified
 After completing this session the participant should be able to:  Discuss the goals of HIV treatment.  Understand when resistance testing should be.
+ Antiretroviral Agents: HIV & AIDS Shaw Vonder Hoya.
HIV Care 2010: The 3 rd Revolution in HIV treatment Chris Farnitano, MD Noon Conference February 11, 2010.
HIV Lifecycle and Mechanisms of Antiretroviral Therapy
Track B Workshop Controversies in the Management of HIV-positive Adults: A Case-Based Approach Sasisopin Kiertiburanakul, MD, MHS Associate Professor Department.
Dr Emmanuel Nsutebu Consultant Infectious Diseases Physician Tropical and Infectious Diseases Unit Royal Liverpool Hospital HIV “Myths, controversies and.
Human Immunodeficiency Virus and Antiretroviral Therapy Lucille Sanzero Eller, PhD, RN Associate Professor Rutgers, The State University of New Jersey.
Human Immunodeficiency Virus and Antiretroviral Therapy
Presented by: Siti Rohaizah bt Othman. Arv DRUGS AVAILABLE IN UMMC Combivir (Lamivudine + Zidovudine) Stocrin (Efavirenz 600mg) Kaletra (Lopinavir 200mg.
ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.
Introduction to new drugs: I-Base training London - May 2007 Introduction to new drugs African Treatment Advocacy Training 31 May 2007 Simon Collins
The UNAIDS Investment Framework: Setting priorities for HIV prevention in today’s global economic climate Resource allocation decisions for HIV prevention.
HIV Update Dr Hugh Mc Gann Consultant in Infectious Diseases
ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD. Use of ARV Drugs by HIV-Infected Pregnant Women and Their Infants  Considerations for choice of ARV drugs.
Understanding mucosal immunity and HIV transmission: the way to new prevention technologies Robin Shattock Centre for Infection, Division of Cellular &
HIV Therapy Experience is the Best Teacher David K. Stein, M.D. Director, Adult HIV Research Activities Jacobi Medical Center Associate Professor of Clinical.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 93 Antiviral Agents II: Drugs for HIV Infection and Related.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
© IAS–USA Johnson VA et al. Top Antivir Med. 2011;19(4): Updates, user notes, and references available at Mutations in the.
Medicines Patent Pool and Seychelles A primer For more information visit:
Indications for Initiation of ARV Therapy in Children Age >1 Year Clinical Category CD4 + Cell Percentage Plasma HIV RNA Copy Number Recommendation AIDS.
Measuring Adherence to Chronic Disease Treatment Using Dispensing Data: An Example from Thailand Sauwakon Ratanawijitrasin, PhD Sanita Hirunrassamee, PhD.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Current Concepts in HIV/AIDS A Pharmacy Perspective Carol Schneiderman, Pharm D Clinical Pharmacist, University of Arizona.
Why African Americans Must Understand and Participate in Clinical Trials and Vaccines Virginia A. Caine, M.D. Associate Professor of Medicine Division.
Ministry of Health Health Surveillance Secretariat NATIONAL STD/AIDS PROGRAMME.
AIDS ΘΕΡΑΠΕΙΑ Κατευθυντήριες Οδηγίες ΓΕΩΡΓΙΟΣ ΠΑΝΟΣ BSc(Biomed.Eng.), CEng, MIET, MD, PhD, DTM&H(Lon), FRCP Αν. Καθηγητής Παθολογίας & Λοιμωδών Νοσημάτων.
HIV: WHAT IS NEW? DR NYA EBAMA, M.D. LOWCOUNTRY INFECTIOUS DISEASES, PA CARETEAM PLUS, INC SEPTEMBER 18, 2015.
Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.
MANAGEMENT OF HIV Involves both treatment of the virus and prevention of opportunistic infections. The aims of HIV treatment are : Reduce the viral load.
ANTIVIRAL THERAPY DR FATAI OLUYADI USMLEINCLINED.COM 1.
© IAS–USA Johnson VA et al. Top Antivir Med. 2013;21(1):4-12. Updates, user notes, and references available at Mutations in the Reverse.
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 94 Antiviral Agents II: Drugs for HIV Infection and.
Phase 3 Treatment-Naïve and Treatment-Experienced
Antiretroviral Therapy (ART)
TREATMENT OF HIV.
Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.
ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:
Drug Pricing Policies and Challenges
Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial
HIV/AIDS By: Khatiga Shervani , Karla Molina, Tiffany Cordero, and Claribel Torres Ms. Green and Ms. Geshke Period 3.
Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses 
Giới thiệu về điều trị ARV
Antiviral Drugs Chapter 45.
Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV
School of Pharmacy, University of Nizwa
Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.
Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and.
Forecasting for ARVs medicines
F. Canducci, B. Barda, E. Ceresola, V. Spagnuolo, M. Sampaolo, E
Antiretroviral therapy and its complications
Figure 1. Rate of PDR in infants according to ARV exposure
Tertiary structures of HIV-1 reverse transcriptase and chemical formulas of NRTIs and NNRTIs. (A) HIV-1 RT complexed with dsDNA and zidovudine triphosphate.
Tertiary structures of HIV-1 protease and chemical formulas of HIV protease inhibitors. Tertiary structures of HIV-1 protease and chemical formulas of.
ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE
Presentation transcript:

Solange Arazi Caillaud. MD Emiliano Bissio. MD María Ester Lázaro. MD

99% of men love Football 99% of what she says about us, is unfortunatly true Less than 30% of argentines dance tango 80% of argentines drink mate

Total Population 40 Millions HIV infected People who know their HIV status (50%) People on follow up % public health 31% security system

DISTRIBUTION OF HIV INFECTED PATIENTS ARGENTINA Buenos Aires city and suburbs: 44% Central Area: 27%

Routes of transmission Argentina ( ) MenWomen 48% 34% 87%

CD4 Viral load Resistance test PCR-HIV(MTCT) ARV Drugs for treatment and prophylaxis of opportunistic infections NRTI Zidovudine Lamivudine Stavudine Didanosine Tenofovir Abacavir Emtricitabine+ tenofovir NNRTI Nevirapine Efavirenz Etravirine PI Nelfinavir Indinavir Ritonavir Saquinavir Amprenavir Lopinavir+ritonavir Fosamprenavir Tipranavir Atazanavir Darunavir Integrase Inhibitor Raltegravir Co-Receptor antagonist Maraviroc Fusion Inhibitor Enfuvirtide ( T20)

Rate of MTCT per newborn Age at diagnosis of the children perinatally infected. N= % 2 years old Number of children Age (years)

Thanks EACS for this great oportunity!